心脏锐器伤的救治

心脏锐器伤是致命性损伤,随着社会的发展,其发生率有增高的趋势。它属于外科急症,具有死亡率高、需要在事发地医院就地抢救的临床特点。本文复习国内外文献资料,对心脏锐器伤的流行病学特点与变迁、快速诊断的方法、抢救与后续治疗方面及亚临床的前瞻性研究等进行综述。     

Beneficial effect of hyperbaric oxygenation on liver regeneration in cirrhosis

BACKGROUND: Underlying hepatic injury and cirrhosis are leading factors that interfere with the post-operative liver regeneration and function. Hyperbaric oxygenation (HBO) has been reported to ameliorate the ischemia-reperfusion injury of the liver, to induce compensatory hypertrophy of the predicted remnant liver in rats after portal vein ligation and to augment liver regeneration after hepatectomy in non-cirrhotic rats. Our aim was to determine the effect of HBO treatment on liver regeneration after partial hepatectomy in normal and cirrhotic mice in this experimental study. MATERIALS AND METHODS: The effect of HBO on liver regeneration was studied in a mice model combining carbon tetrachloride induced cirrhosis and partial hepatectomy. Mice were divided into four groups: Control, cirrhotic, non-cirrhotic HBO-treated, and cirrhotic HBO-treated. All animals underwent 40% hepatectomy. Liver regeneration was evaluated by the proliferating cell nuclear antigen-labeling index. Serum aspartate aminotransferase and alanine aminotransferase levels were measured to evaluate liver injury. RESULTS: Serum alanine aminotransferase and aspartate aminotransferase levels were significantly decreased in HBO-treated cirrhotic group compared to cirrhosis group after hepatectomy (P = 0.001 and P = 0.014, respectively). The proliferating cell nuclear antigen labeling index was significantly higher in HBO treated cirrhotic group than in cirrhotic group after hepatectomy (P = 0.022). CONCLUSIONS: Our results suggest that HBO treatment improves liver functions and augments hepatocyte regeneration in cirrhotic mice after hepatectomy. Post-operative HBO treatment may have a beneficial effect on post-operative liver function and regeneration in cirrhotic patients.     

Preoperative (neoadjuvant) systemic treatment of breast cancer

Preoperative systemic treatment (PST) is a valid option not only for advanced breast cancer stages but also for operable breast cancer. We know that disease-free and overall survival after PST are equivalent to those after adjuvant therapy. Furthermore, PST is able to improve surgical treatment by increasing the rate of breast conservation surgery, which minimises psychological distress for patients fearing mastectomy. Response to PST is a predictor of long-term outcome and gives prognostic information after a short-term interval in contrast to adjuvant trials, which do not show their results until after a 5- to 10-year follow-up. More often, endocrine non-responsive tumours demonstrate a pathological complete response (pCR). Thus, PST can change the formerly bad prognostic marker into one that indicates a favourable prognosis if pCR is achieved by PST. If PST is performed outside clinical trials, anthracycline/taxane-based regimens should be used, especially in sequential prolonged schedules. The use of aromatase inhibitors in preoperative endocrine therapy in elderly postmenopausal patients with endocrine-responsive breast cancer yields a larger proportion of local response than tamoxifen. The duration of PST is not well established, but at least four cycles of chemotherapy should be administered and endocrine therapy needs a minimal time to show greatest benefit when given for at least 3-4 months . The concurrent use of chemotherapy and endocrine drugs did not show any benefit, even in endocrine-responsive tumours and should therefore be avoided. Sentinel node biopsy is a reasonable approach, but this technique should be reserved for experienced surgeons. PCR is the most important surrogate marker of PST, demonstrating an improved disease-free and overall survival. But even if pCR of the primary tumour is achieved, the detection of lymph node metastases is the most important prognostic factor, indicating a substantial risk of cancer recurrence. PST will lead to individualised (tailored) treatment in patients with primary breast cancer.     

Immunosuppression: evolution in practice and trends, 1993–2003

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. This period is of interest because it was during this time that the Food and Drug Administration (FDA) expanded the variety of medications to allow for alternatives in immunosuppressive management. An organ-by-organ review of SRTR data identifies several important trends. Antibody induction continues to be used for the majority of kidney (70%) , simultaneous pancreas-kidney (SPK, 79%) pancreas after kidney (PAK, 74%), and intestine recipients (74%). It is used for under half of thoracic organ recipients and remains uncommon for liver transplant recipients (20%). The type of antibody preparation utilized has shifted from muromonab-CD3 and horse ATG to rabbit ATG and monoclonal anti-IL-2 receptor antagonists. Calcineurin inhibitors continue to be used for maintenance immunosuppression for most recipients, although there has been a shift from cyclosporine to tacrolimus. A clear transition is apparent in the choice of antimetabolite from azathioprine to mycophenolate mofetil. Although corticosteroids continue to be used as maintenance immunosuppression for most recipients prior to discharge, there is evidence that efforts of steroid avoidance protocols are having an impact across all organs, as slight decreases in their use have been observed.     

Single-injection thoracic paravertebral block for postoperative pain treatment after thoracoscopic surgery

Background. Thoracoscopic surgery can be associated with considerablepostoperative pain. While the benefits of paravertebral blockon pain after thoracotomy have been demonstrated, no investigationson the effects of paravertebral block on pain after thoracoscopyhave been conducted. We tested the hypothesis that a single-injectionthoracic paravertebral block, performed preoperatively, reducespain scores after thoracoscopic surgery. Methods. Of 45 patients recruited, 40 completed the study. Theywere randomly allocated to two groups: the paravertebral groupreceived i.v. patient-controlled analgesia (PCA) with morphineplus single-injection thoracic paravertebral block with bupivacaine0.375% and adrenaline 1:200 000 0.4 ml kg^–1 (n=20). Thecontrol group was treated with a back puncture without injectionand morphine PCA (n=20). Results. The main outcomes recorded during 48 h after surgerywere pain scores using the visual analogue scale (VAS, 0–100).Secondary outcomes were cumulative morphine consumption andpeak expiratory flow rate (PEFR). Half an hour and 24 h aftersurgery, median (25th–75th percentiles) VAS on coughingin the paravertebral group was 31.0 (20.0–55.0) and 30.5(17.5–40.0) respectively and in the control group it was70.0 (30.0–100.0) and 50.0 (25.0–75.0) respectively.The difference between the groups over the whole observationperiod was statistically significant (P<0.05). Twenty-fourand 48 h after surgery, median (25th–75th percentiles)cumulative morphine consumption (mg) was 49.0 (38.3–87.0)and 69.3 (38.8–118.5) respectively in the paravertebralgroup and 51.2 (36.0–84.1) and 78.1 (38.4–93.1)in the control group (statistically not significant). No differenceswere found in PEFR or the incidence of any side-effects betweengroups. Conclusion. We conclude that single-shot preoperative paravertebralblock improves post-operative pain treatment after thoracoscopicsurgery in a clinically significant fashion.      

Pulmonary blastoma

We describe a resected pulmonary blastoma in an 84-year-old male, the oldest of previously reported patients. A chest X-ray showed a 2 cm-sized abnormal shadow in the left lung field. Five months later computed tomography demonstrated a well-demarcated heterogenous mass, measuring 12 cm in diameter, in the left lower lobe of the lung. This mass was diagnosed as a carcinoma using echo-guided percutaneous biopsy. The patient underwent a left lower lobectomy. The resected specimen revealed the tumor to be a pulmonary blastoma arising from lung tissue. Preoperative diagnosis of pulmonary blastoma is extremely difficult because of the histological heterogeneity of tumor. Since it has been noted that pulmonary blastoma rapidly progresses in a short period of time, surgical treatment should be undertaken as quickly as possible when such a tumor is suspected.     

Surgical treatment of extrahepatic portal vein aneurysm: A case report and review of the literature

A portal vein aneurysm, first reported by Barzilai and Kleckner in 1956, 1 is a rare clinical entity caused by portal hypertension or the malformation of veins. The frequent application of radiological imaging for diagnosis and screening of abdominal disorders accounts for the increasing number of case reports over the past 10 years; however, fewer than 60 cases have been reported in the English language literature to date. Herein we report a woman with an extrahepatic portal vein aneurysm, and present a review of literature relating to etiology, clinical significance and management strategies.     

胃肠道恶性肿瘤术后腹腔内温热化疗灌注的应用

目的:探讨胃肠道恶性肿瘤术后采用腹腔内温热化疗的疗效。方法:选择Ⅱ～Ⅳ期胃肠道恶性肿瘤术后患者60例,32例作为治疗组,采用腹腔内温热化疗 静脉化疗,28例作为对照组,采用常规静脉化疗。结果:治疗组腹腔复发率及转移率明显低于对照组(P<0.01)。治疗组3年及5年的生存率明显高于对照组(P<0.01)。结论:胃肠道恶性肿瘤术后腹腔内温热化疗 静脉化疗,不但能有效降低胃肠道恶性肿瘤术后腹腔复发及转移,而且能提高3年及5年的生存率。     

青少年Pilon骨折的治疗

目的探讨青少年Pilon骨折的特点、治疗方法及其并发症。方法对1990年4月～2003年12月期间治疗的13例青少年胫骨Pilon骨折病例进行随访分析。按Merv—Letts分型：Ⅰ型5例，Ⅱ型6例，Ⅲ型2例。骨牵引治疗2例，有限内同定8例，有限内固定结合外固定支架3例。结果所有患者平均随访24个月，按Helfet踝关节功能评价：优8例，良4例，差1例，优良率92．3％。并发症：皮肤坏死2例，创伤性关节炎4例，骨骺早闭3例，畸形愈合1例，骨延迟愈合1例，外固定支架钉道感染1例，总体并发症38．5％。结论青少年Pilon骨折应根据其分型采用不同的治疗方案：疗效与创伤程度有关：Ⅲ犁骨折有较高的并发痹。